Timothy J. Yeatman

Executive Vice President Trans Research/President M2 at H. Lee Moffitt Cancer Center and Research Institute, Inc.

Timothy J. Yeatman

Timothy J. Yeatman

Executive Vice President Trans Research/President M2 at H. Lee Moffitt Cancer Center and Research Institute, Inc.

Biography

Timothy J. Yeatman
Executive Vice President and Founding Chief Scientific Officer.
Moffitt Cancer Center.

Timothy J. Yeatman, M.D., F.A.C.S., is the Executive Vice President and Founding Chief Scientific Officer of M2Gen and Division Head of Hepatobiliary Oncology at Moffitt Cancer Center. He serves as a professor at the University of South Florida College of Medicine.
He received his medical degree from Emory University, completed his surgical internship and residency at the University of Florida and did a Surgical Oncology Fellowship at M. D. Anderson Cancer Center. Dr. Yeatman has published more than 120 articles in the top peer-reviewed journals in his field including the prestigious Nature Genetics, Nature Reviews Cancer, as well as the Journal of the National Cancer Institute, and Cancer Research.
Dr. Yeatman has received numerous honors and awards including the James IV Association of Surgeons Traveling Fellowship, Europe 2001; the Center Director's Award for Outstanding Research at Moffitt Cancer Center (1998, 1997, 1995); and the James Ewing Foundation Trainee Award, Society of Surgical Oncology, 1997. Dr. Yeatman has been continuously funded over the course of the past 12 years through grants from the NCI and the American Cancer Society. Currently, he is funded by two NIH grants worth more than $5 million in total costs.

Dr. Yeatman has focused his research on the management of gastrointestinal malignancies with a special research emphasis on using genome scale microarrays to identify the molecular signatures of cancer that provide diagnosis, prognosis and response to therapy. He recently compared microarray data of 540 human tumors of 21 different tumor types with the diagnoses obtained from tumor biopsies. He found that microarray was 88 percent accurate in predicting all tumor types. The results of his investigation, the first such work to be reported in this depth, appeared in the January 2004 issue of the American Journal of Pathology. In addition, he and his colleagues have detected 340 new tumor markers and more than 100 tumor progression markers whose expression correlated with progressing tumor stage. Some of these markers may be useful in the clinical management of colon cancer patients because of their capacity to detect and predict the stage of cancer. Dr. Yeatman has been appointed to the Directorship of Total Cancer Care, a large research project that will lead to personalized cancer care.

Overview
RelSci Relationships

399

Relationships
RelSci Relationships are individuals Timothy J. Yeatman likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at H. Lee Moffitt Cancer Center and Research Institute, Inc.

Relationship likelihood: Average

Executive Vice President & General Counsel at H. Lee Moffitt Cancer Center and Research Institute, Inc.

Relationship likelihood: Average

Chief Financial Officer & Executive Vice President at H. Lee Moffitt Cancer Center and Research Institute, Inc.

Relationship likelihood: Average

Owner at H. Lee Moffitt Cancer Center and Research Institute, Inc.

Relationship likelihood: Average

Chief Nursing Officer & Vice President at H. Lee Moffitt Cancer Center and Research Institute, Inc.

Relationship likelihood: Average

Chief Academic Officer at H. Lee Moffitt Cancer Center and Research Institute, Inc.

Relationship likelihood: Average

Chief Human Resources Officer at H. Lee Moffitt Cancer Center and Research Institute, Inc.

Relationship likelihood: Average

President at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.

Relationship likelihood: Average

Chief Medical Officer at H. Lee Moffitt Cancer Center and Research Institute, Inc.

Relationship likelihood: Average

Partner at H. Lee Moffitt Cancer Center and Research Institute, Inc.

Relationship likelihood: Average

Paths to Timothy J. Yeatman
Potential Connections via
Relationship Science
You
Timothy J. Yeatman
Executive Vice President Trans Research/President M2 at H. Lee Moffitt Cancer Center and Research Institute, Inc.
Career History
Executive Vice President Trans Research/President M2
Tenure Unconfirmed

Moffitt Cancer Center in Tampa, Florida, has made a lasting commitment to the prevention and cure of cancer, working tirelessly in the areas of patient care, research and education to advance one step further in fighting this disease. Alan F. List, M.D. President/CEO Translational Research As part of an elite group of National Cancer Institute (NCI) Comprehensive Cancer Centers, Moffitt focuses on the development of early stage translational research aimed at the rapid translation of scientific discoveries to benefit patient care. Tradition of Excellence Since our first patient admission in October 1986, Moffitt physicians, scientists and staff members have worked together to establish a tradition of excellence offered in an atmosphere characterized by kindness, caring and hope. Our future growth in clinical care and research rests firmly on this tradition and makes possible the changes ahead. Mission The mission of Moffitt Cancer Center is to contribute to the prevention and cure of cancer. Vision Our vision is "to be the leader in scientific discovery and translation into compassionate care, cures, and prevention of cancer for our community and the world." As we grow to fulfill our mission, we will continue to be distinguished by our compassionate and effective patient care. Institutional Values S cientific, educational, and patient care excellence U nity in pursuit of our mission C reativity C ompassion for our patients and their families E mployees, volunteers, and faculty are our most prized resources S tewardship S ocial responsibility and ethics of the highest standard Moffitt Facts Moffitt Cancer Center is a not-for-profit institution. It includes private patient rooms, the Southeast’s largest Blood and Marrow Transplant Program, outpatient treatment programs that record more than 328,300 visits a year, the Moffitt Research Center, Moffitt Cancer Center at International Plaza, and Moffitt Cancer Center Screening and Prevention. In 2003, Moffitt opened its doors to the Muriel Rothman Building (Clinic) and Vincent A. Stabile Research Building. These two buildings dramatically increased the existing research and outpatient clinical space to better serve our patients.

Chief Scientist
Prior - 2016

CASIS MANAGES, PROMOTES, AND BROKERS RESEARCH FOR THE ISS U.S. NATIONAL LABORATORY.

Political Donations
$250
2009

Representative at Office of the Representative from Florida's 13th District, Charlie Crist

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Timothy J. Yeatman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Timothy J. Yeatman's profile does not indicate a business or promotional relationship of any kind between RelSci and Timothy J. Yeatman.